The American Society of Clinical Oncology said it opposes “right-to-try” laws that allow terminally ill patients to request access to investigational drugs directly from manufacturers, bypassing a layer of review, where FDA assesses the available data to review and benefits of the treatment on behalf of the patient.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe